850 related articles for article (PubMed ID: 33139569)
1. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.
Li W; Chen C; Drelich A; Martinez DR; Gralinski LE; Sun Z; Schäfer A; Kulkarni SS; Liu X; Leist SR; Zhelev DV; Zhang L; Kim YJ; Peterson EC; Conard A; Mellors JW; Tseng CK; Falzarano D; Baric RS; Dimitrov DS
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29832-29838. PubMed ID: 33139569
[TBL] [Abstract][Full Text] [Related]
2. Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models.
Li W; Drelich A; Martinez DR; Gralinski L; Chen C; Sun Z; Schäfer A; Leist SR; Liu X; Zhelev D; Zhang L; Peterson EC; Conard A; Mellors JW; Tseng CT; Baric RS; Dimitrov DS
bioRxiv; 2020 Jun; ():. PubMed ID: 32511413
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
5. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Liu Z; VanBlargan LA; Bloyet LM; Rothlauf PW; Chen RE; Stumpf S; Zhao H; Errico JM; Theel ES; Liebeskind MJ; Alford B; Buchser WJ; Ellebedy AH; Fremont DH; Diamond MS; Whelan SPJ
Cell Host Microbe; 2021 Mar; 29(3):477-488.e4. PubMed ID: 33535027
[TBL] [Abstract][Full Text] [Related]
8. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
9. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
[TBL] [Abstract][Full Text] [Related]
11. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
[TBL] [Abstract][Full Text] [Related]
12. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
Cohen AA; Gnanapragasam PNP; Lee YE; Hoffman PR; Ou S; Kakutani LM; Keeffe JR; Wu HJ; Howarth M; West AP; Barnes CO; Nussenzweig MC; Bjorkman PJ
Science; 2021 Feb; 371(6530):735-741. PubMed ID: 33436524
[TBL] [Abstract][Full Text] [Related]
13. High Potency of a Bivalent Human V
Li W; Schäfer A; Kulkarni SS; Liu X; Martinez DR; Chen C; Sun Z; Leist SR; Drelich A; Zhang L; Ura ML; Berezuk A; Chittori S; Leopold K; Mannar D; Srivastava SS; Zhu X; Peterson EC; Tseng CT; Mellors JW; Falzarano D; Subramaniam S; Baric RS; Dimitrov DS
Cell; 2020 Oct; 183(2):429-441.e16. PubMed ID: 32941803
[TBL] [Abstract][Full Text] [Related]
14. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035
[TBL] [Abstract][Full Text] [Related]
15. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.
Passariello M; Gentile C; Ferrucci V; Sasso E; Vetrei C; Fusco G; Viscardi M; Brandi S; Cerino P; Zambrano N; Zollo M; De Lorenzo C
Sci Rep; 2021 May; 11(1):11046. PubMed ID: 34040046
[TBL] [Abstract][Full Text] [Related]
16. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
17. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection.
Clark NM; Janaka SK; Hartman W; Stramer S; Goodhue E; Weiss J; Evans DT; Connor JP
PLoS One; 2022; 17(3):e0257930. PubMed ID: 35259162
[TBL] [Abstract][Full Text] [Related]
20. Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies.
Lou Y; Zhao W; Wei H; Chu M; Chao R; Yao H; Su J; Li Y; Li X; Cao Y; Feng Y; Wang P; Xia Y; Shang Y; Li F; Ge P; Zhang X; Gao W; Song G; Du B; Liang T; Qiu Y; Liu M
Biotechnol J; 2021 Nov; 16(11):e2100207. PubMed ID: 34379353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
